Neuroxelin dosage and protocol
Neuroxelin is a synthetic neuroprotective peptide studied for its potential to reduce excitotoxic neuronal damage, modulate neuroinflammation, and support neural repair following brain injury or stroke. Related to nerinetide-class peptides that interfere with PSD-95/NMDA receptor excitotoxic signaling and apoE-mimetic peptides that reduce microglial activation and cytokine release.
- Vial size: 48 mg
- Reconstitution: 3 mL bacteriostatic water
- Concentration: 16 mg/mL
- Administration: subcutaneous
Research areas
- Neuroprotection
- Cognitive Recovery
- Brain Injury
- Neuroinflammation
- Neurogenesis
Quick start
- Reconstitute: Add 3.0 mL bacteriostatic water to the 48 mg vial for about 16 mg/mL
- Typical dose: 500 mcg once daily (weeks 1-4), then 750 mcg once daily (weeks 5-8)
- Easy measuring: At 16 mg/mL, 1 unit = 0.01 mL = 160 mcg on a U-100 syringe; 500 mcg is about 3.1 units and 750 mcg about 4.7 units
- Storage: Lyophilized at -20°C; after reconstitution refrigerate at 2-8°C and use within 4 weeks
Dosing protocol
| Phase | Dose | Frequency | Volume |
|---|---|---|---|
| Weeks 1–4 | 500mcg | Once daily (morning) | 0.03mL |
| Weeks 5–8 | 750mcg | Once daily (morning) | 0.047mL |
How it works
Neuroxelin is described as a synthetic neuroprotective peptide, but it does not appear as a named compound in the peer-reviewed literature, and no published structure, pharmacokinetic data or trial results could be identified for it under this name. Its proposed mechanism is borrowed from two better-characterised peptide classes: PSD-95 inhibitors such as nerinetide, which uncouple NMDA receptors from neuronal nitric oxide synthase and so blunt the excitotoxic cascade that follows ischemia, and apoE-mimetic peptides, which act on microglia to dampen cytokine release and inflammatory signalling after brain injury. The evidence for those parent classes is mixed. Nerinetide reduced infarct size in rodent and primate stroke models, but in a large phase 3 thrombectomy trial it did not improve overall functional outcomes, with a possible benefit confined to patients who had not received alteplase; a follow-up trial in that subgroup did not confirm a clear benefit. ApoE-mimetic peptides have reduced neuroinflammation and improved functional recovery in rodent models of traumatic brain injury and haemorrhage, with only small early-phase human studies. Any effects attributed to Neuroxelin itself are therefore extrapolated rather than demonstrated. Readers should treat this record as a hypothesis built on related compounds, not as a peptide with an established research profile.
Reconstitution steps
- Allow lyophilized vial to reach room temperature before opening
- Draw 3.0mL bacteriostatic water with a sterile syringe
- Inject slowly down the vial wall; avoid foaming
- Gently swirl/roll until dissolved (do not shake)
- Label with concentration (16mg/mL) and date; refrigerate at 2–8°C, protected from light
Storage
Store lyophilized at −20°C (−4°F) in dry, dark conditions. After reconstitution, refrigerate at 2–8°C; use within 4 weeks. Avoid freeze–thaw cycles.
Important notes
- Research use only
- Conservative dose tier: 250mcg/day; Typical: 500mcg/day; Aggressive: 1000mcg/day
- For doses ≤6 units, use 30- or 50-unit syringes for improved accuracy
- Rotate injection sites (abdomen, thighs, upper arms) to prevent tissue irritation
- Possible mild injection-site reactions; rotate sites to minimize
- Administer at the same time each morning for consistency
Supplies
- Bacteriostatic water
- Insulin syringes (U-100, 30- or 50-unit preferred)
- Alcohol swabs